OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders
Karin Schad, Katrin Baumann Conzett, Marie Zipser, et al.
Clinical Cancer Research (2010) Vol. 16, Iss. 3, pp. 1058-1064
Open Access | Times Cited: 66
Karin Schad, Katrin Baumann Conzett, Marie Zipser, et al.
Clinical Cancer Research (2010) Vol. 16, Iss. 3, pp. 1058-1064
Open Access | Times Cited: 66
Showing 1-25 of 66 citing articles:
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto, Dirk Schadendorf, Carola Berking, et al.
The Lancet Oncology (2013) Vol. 14, Iss. 3, pp. 249-256
Closed Access | Times Cited: 620
Paolo A. Ascierto, Dirk Schadendorf, Carola Berking, et al.
The Lancet Oncology (2013) Vol. 14, Iss. 3, pp. 249-256
Closed Access | Times Cited: 620
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Grace K. Dy, Alex A. Adjei
CA A Cancer Journal for Clinicians (2013) Vol. 63, Iss. 4, pp. 249-279
Open Access | Times Cited: 313
Grace K. Dy, Alex A. Adjei
CA A Cancer Journal for Clinicians (2013) Vol. 63, Iss. 4, pp. 249-279
Open Access | Times Cited: 313
Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
John M. Kirkwood, Lars Bastholt, Caroline Robert, et al.
Clinical Cancer Research (2011) Vol. 18, Iss. 2, pp. 555-567
Open Access | Times Cited: 269
John M. Kirkwood, Lars Bastholt, Caroline Robert, et al.
Clinical Cancer Research (2011) Vol. 18, Iss. 2, pp. 555-567
Open Access | Times Cited: 269
Nail toxicities induced by systemic anticancer treatments
Caroline Robert, V. Sibaud, Christina Mateus, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 4, pp. e181-e189
Closed Access | Times Cited: 172
Caroline Robert, V. Sibaud, Christina Mateus, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 4, pp. e181-e189
Closed Access | Times Cited: 172
Cutaneous adverse effects of targeted therapies
James B. Macdonald, Brooke Macdonald, Loren E. Golitz, et al.
Journal of the American Academy of Dermatology (2015) Vol. 72, Iss. 2, pp. 221-236
Closed Access | Times Cited: 171
James B. Macdonald, Brooke Macdonald, Loren E. Golitz, et al.
Journal of the American Academy of Dermatology (2015) Vol. 72, Iss. 2, pp. 221-236
Closed Access | Times Cited: 171
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Caroline Robert, Reinhard Dummer, Ralf Gutzmer, et al.
The Lancet Oncology (2013) Vol. 14, Iss. 8, pp. 733-740
Closed Access | Times Cited: 162
Caroline Robert, Reinhard Dummer, Ralf Gutzmer, et al.
The Lancet Oncology (2013) Vol. 14, Iss. 8, pp. 733-740
Closed Access | Times Cited: 162
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
U. Urner‐Bloch, Martin Urner, P. Stieger, et al.
Annals of Oncology (2014) Vol. 25, Iss. 7, pp. 1437-1441
Open Access | Times Cited: 126
U. Urner‐Bloch, Martin Urner, P. Stieger, et al.
Annals of Oncology (2014) Vol. 25, Iss. 7, pp. 1437-1441
Open Access | Times Cited: 126
Systemic Treatment of Melanoma
Reinhard Dummer, Simone M. Goldinger
(2024), pp. 1-15
Closed Access | Times Cited: 9
Reinhard Dummer, Simone M. Goldinger
(2024), pp. 1-15
Closed Access | Times Cited: 9
RAF inhibition and induction of cutaneous squamous cell carcinoma
Caroline Robert, Jean‐Philippe Arnault, Christine Mateus
Current Opinion in Oncology (2010) Vol. 23, Iss. 2, pp. 177-182
Closed Access | Times Cited: 118
Caroline Robert, Jean‐Philippe Arnault, Christine Mateus
Current Opinion in Oncology (2010) Vol. 23, Iss. 2, pp. 177-182
Closed Access | Times Cited: 118
RASopathic Skin Eruptions during Vemurafenib Therapy
Jeannine D. Rinderknecht, Simone M. Goldinger, Sima Rozati, et al.
PLoS ONE (2013) Vol. 8, Iss. 3, pp. e58721-e58721
Open Access | Times Cited: 82
Jeannine D. Rinderknecht, Simone M. Goldinger, Sima Rozati, et al.
PLoS ONE (2013) Vol. 8, Iss. 3, pp. e58721-e58721
Open Access | Times Cited: 82
MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects
U. Urner‐Bloch, Martin Urner, Nicoletta F. Jaberg-Bentele, et al.
European Journal of Cancer (2016) Vol. 65, pp. 130-138
Open Access | Times Cited: 67
U. Urner‐Bloch, Martin Urner, Nicoletta F. Jaberg-Bentele, et al.
European Journal of Cancer (2016) Vol. 65, pp. 130-138
Open Access | Times Cited: 67
BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
Jacek Mackiewicz, Andrzej Maćkiewicz
Współczesna Onkologia (2018) Vol. 2018, Iss. 1, pp. 68-72
Open Access | Times Cited: 60
Jacek Mackiewicz, Andrzej Maćkiewicz
Współczesna Onkologia (2018) Vol. 2018, Iss. 1, pp. 68-72
Open Access | Times Cited: 60
High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade
Michael K. Kießling, Patrick A. Oberholzer, Chandrani Mondal, et al.
Blood (2011) Vol. 117, Iss. 8, pp. 2433-2440
Open Access | Times Cited: 75
Michael K. Kießling, Patrick A. Oberholzer, Chandrani Mondal, et al.
Blood (2011) Vol. 117, Iss. 8, pp. 2433-2440
Open Access | Times Cited: 75
Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors
Saveria Pastore, Daniela Lulli, Giampiero Girolomoni
Archives of Toxicology (2014) Vol. 88, Iss. 6, pp. 1189-1203
Closed Access | Times Cited: 66
Saveria Pastore, Daniela Lulli, Giampiero Girolomoni
Archives of Toxicology (2014) Vol. 88, Iss. 6, pp. 1189-1203
Closed Access | Times Cited: 66
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management.
Elisabeth Livingstone, Lisa Zimmer, Julia Vaübel, et al.
PubMed (2014) Vol. 3, Iss. 3, pp. 29-29
Closed Access | Times Cited: 59
Elisabeth Livingstone, Lisa Zimmer, Julia Vaübel, et al.
PubMed (2014) Vol. 3, Iss. 3, pp. 29-29
Closed Access | Times Cited: 59
Developments in targeted therapy in melanoma
Valerie C. Amann, Egle Ramelyte, S. Thurneysen, et al.
European Journal of Surgical Oncology (2016) Vol. 43, Iss. 3, pp. 581-593
Open Access | Times Cited: 59
Valerie C. Amann, Egle Ramelyte, S. Thurneysen, et al.
European Journal of Surgical Oncology (2016) Vol. 43, Iss. 3, pp. 581-593
Open Access | Times Cited: 59
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
Xiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
European Journal of Cancer (2024) Vol. 202, pp. 114008-114008
Closed Access | Times Cited: 5
Xiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
European Journal of Cancer (2024) Vol. 202, pp. 114008-114008
Closed Access | Times Cited: 5
Cutaneous adverse events of pan-RAF inhibitor naporafenib (LXH254) containing drug combinations in NRAS-mutant metastatic melanoma
Sabine Hoheisel, Jacopo Roggero, Joanna Mangana, et al.
EJC Skin Cancer (2025), pp. 100283-100283
Open Access
Sabine Hoheisel, Jacopo Roggero, Joanna Mangana, et al.
EJC Skin Cancer (2025), pp. 100283-100283
Open Access
Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2
Takayuki Yoshida, Junya Kakegawa, Takayuki Yamaguchi, et al.
Oncotarget (2012) Vol. 3, Iss. 12, pp. 1533-1545
Open Access | Times Cited: 57
Takayuki Yoshida, Junya Kakegawa, Takayuki Yamaguchi, et al.
Oncotarget (2012) Vol. 3, Iss. 12, pp. 1533-1545
Open Access | Times Cited: 57
Cutaneous Side Effects of New Antitumor Drugs
Ralf Gutzmer, Andreas Wollenberg, Selma Ugurel, et al.
Deutsches Ärzteblatt international (2012)
Open Access | Times Cited: 48
Ralf Gutzmer, Andreas Wollenberg, Selma Ugurel, et al.
Deutsches Ärzteblatt international (2012)
Open Access | Times Cited: 48
Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
Simone M. Goldinger, Carla Murer, P. Stieger, et al.
European Journal of Cancer Supplements (2013) Vol. 11, Iss. 2, pp. 92-96
Open Access | Times Cited: 47
Simone M. Goldinger, Carla Murer, P. Stieger, et al.
European Journal of Cancer Supplements (2013) Vol. 11, Iss. 2, pp. 92-96
Open Access | Times Cited: 47
The role of MEK inhibitors in the treatment of metastatic melanoma
Antonio M. Grimaldi, Ester Simeone, Paolo A. Ascierto
Current Opinion in Oncology (2014) Vol. 26, Iss. 2, pp. 196-203
Closed Access | Times Cited: 45
Antonio M. Grimaldi, Ester Simeone, Paolo A. Ascierto
Current Opinion in Oncology (2014) Vol. 26, Iss. 2, pp. 196-203
Closed Access | Times Cited: 45
A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis
Daniella Jenni, Maria B. Karpova, Beda Mühleisen, et al.
ESMO Open (2016) Vol. 1, Iss. 1, pp. e000003-e000003
Open Access | Times Cited: 41
Daniella Jenni, Maria B. Karpova, Beda Mühleisen, et al.
ESMO Open (2016) Vol. 1, Iss. 1, pp. e000003-e000003
Open Access | Times Cited: 41
Insights into melanoma: targeting the mTOR pathway for therapeutics
Helena Pópulo, Paula Soares, José Manuel Lopes
Expert Opinion on Therapeutic Targets (2012) Vol. 16, Iss. 7, pp. 689-705
Closed Access | Times Cited: 42
Helena Pópulo, Paula Soares, José Manuel Lopes
Expert Opinion on Therapeutic Targets (2012) Vol. 16, Iss. 7, pp. 689-705
Closed Access | Times Cited: 42
Side effects of systemic oncological therapies in dermatology
Lisa Zimmer, Julia Vaübel, Elisabeth Livingstone, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2012) Vol. 10, Iss. 7, pp. 475-486
Closed Access | Times Cited: 39
Lisa Zimmer, Julia Vaübel, Elisabeth Livingstone, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2012) Vol. 10, Iss. 7, pp. 475-486
Closed Access | Times Cited: 39
